EMERYVILLE, Calif. & SHANGHAI--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE MKT:NBY), a biopharmaceutical company focusing on the development and commercialization of its non-antibiotic anti-infective products, and China Pioneer Pharma Holdings, Limited (HK Stock Code: 01345), a leading marketer of branded pharmaceutical products and medical devices in China, today announced that China’s Food and Drug Administration has cleared NovaBay’s NeutroPhase® Skin and Wound Cleanser for sale throughout mainland China. NovaBay will be shipping NeutroPhase to China in the fourth quarter of 2014 to support Pioneer’s launch of the product in early 2015.
Chronic non-healing wounds, such as venous stasis ulcers, diabetic ulcers, and pressure ulcers are serious unmet medical needs that affect a patient’s morbidity and mortality. NovaBay’s FDA cleared NeutroPhase has shown remarkable properties in the management of these categories of wounds. As cited in a paper published in the peer-reviewed International Journal of Burns and Trauma, “Patients showed a profound improvement and marked accelerated rates of wound healing using NeutroPhase® with and without NPWT (negative pressure wound therapy). NeutroPhase® was non-toxic to living tissues.”
“The clearance of NeutroPhase in China will help Chinese doctors address major unmet medical needs,” said Paul Li (Mr. Li Xinzhou), Chairman, Executive Director and Chief Executive Officer of Pioneer Pharma. “In China, we are experiencing a ‘catastrophic’ epidemic of diabetes. According to estimates provided by the International Diabetes Federation and the American Medical Association, there are approximately 100 million Chinese already suffering from this condition and its chronic side effects such as diabetic ulcers and other chronic wounds—and their numbers are increasing.”
“At the same time, China has the highest number of reported cases of necrotizing fasciitis, or ‘flesh-eating’ disease of any nation in the world,” Li added. “NeutroPhase will help with both problems.”
NeutroPhase offers new treatment options for both the chronic wounds of diabetes patients and for deadly flesh-eating disease. NovaBay’s NeutroPhase contains a substance produced naturally by the immune system as a first defense against microbial invaders. Laboratory tests show that NeutroPhase not only kills bacteria that infect wounds and cause necrotizing fasciitis, it also neutralizes toxins produced by both bacteria and the immune system that impede healing and destroy healthy tissue. Those properties enable NeutroPhase to address acute infections and thereby help promote the healing of chronic wounds.
Physicians like Dr. John Crew, director of the Advanced Wound Care Center at Seton Medical Center in Daly City, Calif, already routinely manage diabetic ulcers with NeutroPhase to assist healing. Dr. Crew has also developed a method of irrigating flesh-eating wounds with NeutroPhase that has been remarkably successful in saving the lives and limbs of victims of this life-threatening disease, as Crew and NovaBay researchers reported in the journal WOUNDS.
“China is a significant market for NovaBay’s NeutroPhase. The China FDA approval gives us access to this important market. Pioneer Pharma is a major distributor in the region and is NovaBay’s largest single shareholder. We believe that NeutroPhase can bring a major improvement in medical care in China and the quality of these patients’ lives,” said Dr. Ron Najafi, Chairman and CEO of NovaBay. Similar to this healthcare crisis in China, the American Diabetes Association estimates that 29 million Americans suffer from diabetes.
As part of the partnership deal between NovaBay and Pioneer Pharma, the marketing clearance of NeutroPhase by the Chinese Food & Drug Administration triggers a milestone payment of $625,000 to NovaBay from Pioneer.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: Aganocide® compounds, led by auriclosene, and its Hypochlorous Solution Family of Products: NeutroPhase® for wound care, Advanced i-Lid™ Cleanser for the eye care market, and CelleRx™ for the dermatology market.
China Pioneer Pharma is one of the largest comprehensive marketing, promotion and channel management service providers dedicated to imported pharmaceutical products and medical devices in China, Founded in 1996, which has an 18-year operating history. Currently, China Pioneer Pharma has a product portfolio of over 30 pharmaceutical products covering a wide range of therapeutic areas, and medical devices covering four medical specialties. And it has over 240 in-house marketing and promotion employees, over 1,000 third-party promotion partners and over 500 distributors. China Pioneer Pharma sold its products through its nationwide marketing, promotion and channel management service network to a total of over 26,000 hospitals and other medical institutions and over 95,000 pharmacies across 31 provinces, municipalities and autonomous regions in China. For more information, please visit www.pioneer-pharma.com.
This release contains forward-looking statements, which are based upon management's current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding regulatory approvals for our products, the anticipated market acceptance of our products, and the company’s expected future financial results. The words “will” “estimated” “anticipate” and “expect” are intended to identify these forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to difficulties or delays in product development, clinical trials, regulatory approval, production and marketing of the company's products, unexpected adverse side effects or inadequate therapeutic efficacy of the product candidates, the uncertainty of patent protection for the company's intellectual property or trade secrets, the company's ability to obtain additional financing as necessary and unanticipated research and development and other costs. Other risks relating to the company and its products, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay's latest Form 10-K and Form 10-Q filings with the Securities and Exchange Commission, especially under the heading "Risk Factors." The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Stay informed on NovaBay’s progress:
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Join us on Google+
Visit NovaBay’s Website